A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

计划入组 14 人 · 首次发布于 2026 年 2 月 23 日

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

计划入组 152 人 · 首次发布于 2020 年 11 月 25 日

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

计划入组 20 人 · 首次发布于 2026 年 2 月 27 日

dual EGFR/HER2 inhibitors (lung cancer)

Tergenpumatucel-L

DCVAC/LuCa(Sotio)

ADDARIO LUNG CANCER MEDICAL INSTITUTE

United States

European Lung Cancer Working Party

Belgium

Lung Therapeutics, Inc.

United States

Boehringer Ingelheim Prepares for Multiple New Product Launches in 2025 Following Strong R&D Investment

Zongertinib Shows Promise in HER2-Mutated NSCLC: Boehringer Ingelheim Reports Positive Phase Ib Results

Trastuzumab Deruxtecan Shows Promise in HER2-Mutated NSCLC